Pliant Therapeutics Announces Positive Safety and Explorator

Bexotegrast was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis ...

Related Keywords

United States , Christopher Keenan , Clin Gastroenterol Hepatol , Drug Administration , University Of Miami School Medicine , Youtube , Facebook , Pliant Therapeutics Inc , Twitter , Nasdaq , European Medicines Agency , Corporate Communications , Linkedin , Enhanced Liver Fibrosis , Chief Medical Officer , Mayo Score , Demonstrated Antifibrotic Activity , Suspected Moderate , Severe Liver Fibrosis , Itch Numerical Rating Scale , Cynthia Levy , Miami School , Primary Sclerosing , Tuesday September , Pliant Therapeutics , Fast Track Designation , Orphan Drug Designation , Private Securities Litigation Reform Act , Financial Condition , Quarterly Report , Media Contact , Investor Relations , Magn Reson , Markets ,